Drug Trial Radar · NCT05531890
Comparative Bioavailability of Betamethasone Oral Solution Metered Spray (GTX-102) in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Jan 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
48
Actual
Start
Sep 13, 2022
Primary completion
Nov 24, 2022
Study completion May 3, 2023
Sponsor
- Lead sponsor
- Grace Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Randomized, Open-label, Crossover Study to Evaluate the Comparative Bioavailability, Pharmacokinetics, and Safety of GTX-102 Administered as an Oral Spray Compared to Intramuscular Injection - betamethasone and an Oral Solution of Betamethasone in Healthy Subjects. Four groups of subjects will receive 2 treatments each and randomized in 2-way crossover.
Conditions
- Ataxia Telangiectasia
Interventions
GTX-102 medium dose fast Period 1 and Period 2Drug
GTX-102 Betamethasone oral spray medium dose (0.05 mg/kg) administered in Period 1 and Period 2 fast
GTX-102 medium dose slow Period 1 and Period 2Drug
GTX-102 Betamethasone oral spray medium dose (0.05 mg/kg) administered in Period 1 and Period 2 slow
GTX-102 high dose fast Period 1 and Period 2Drug
GTX-102 Betamethasone oral spray high dose (0.1 mg/kg) administered in Period 1 and Period 2 fast
GTX-102 low dose fast Period 1 and Period 2Drug
GTX-102 Betamethasone oral spray high dose (0.025 mg/kg) administered in Period 1 and Period 2 fast
Betamethasone solution as intramuscular injection Period 1 and Period 2Drug
reference product 0.1 mg/kg betamethasone solution as an intramuscular injection
Betamethasone Oral Solution Period 1 and Period 2Drug
Comparator product 0.1 mg/kg betamethasone oral drops solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUC from 0 to 72 hours post-doseTime frame: Up to 72 hours post-dose
- AUCTime frame: Up to infinity
- Cmax from 0 to 72 hours post-doseTime frame: Up to 72 hours post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Research Unit
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.